Cefixime Oral Suspension

Cefixime Oral Suspension belongs to the Suspensions category within the Antibiotics, Pediatric Care, and Infectious Diseases therapeutic segments. It is a third-generation cephalosporin with enhanced activity against Gram-negative organisms.

Cefixime is particularly valued in pediatric practice because of its once-daily dosing regimen, broad spectrum of activity, and proven efficacy against common childhood pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The suspension form is essential for accurate weight-based dosing in children who cannot swallow tablets.

For pharmaceutical marketing companies, Cefixime is a high-prescription pediatric antibiotic with consistent year-round demand, particularly during respiratory illness seasons. Saar Biotech manufactures it from our manufacturing facility in Baddi with validated two-strength suspension quality control and complete 30ml and 60ml packaging options.

At Saar Biotech, we manufacture Cefixime Suspension using a controlled oral suspension manufacturing process that ensures dose uniformity, palatability, and packaging reliability.

• Two-Strength Formulation Capability: We manufacture both 100mg/5ml and 200mg/5ml strengths from the same validated process, allowing B2B partners to launch a complete Cefixime product range covering both pediatric and adult dosing requirements without separate formulation development.

• API Uniformity: Cefixime is a suspended solid that requires careful formulation to prevent sedimentation and inconsistent dosing — a critical failure mode for antibiotic suspensions. Our suspending agent system ensures rapid, uniform re-dispersion after shaking, so every 5ml dose delivers a consistent and predictable active load.

• Taste Masking: Cephalosporins have characteristically bitter taste profiles. We develop mango and mixed fruit-flavoured suspension bases that effectively mask bitterness, ensuring pediatric patients accept each dose without resistance — a genuine commercial differentiator in the competitive pediatric antibiotic segment.

• pH and Stability Management: Cefixime must remain chemically stable for 24 months under tropical storage conditions. Our formulation team selects preservatives, pH buffers, and suspending agents that protect the active from chemical degradation — ensuring the product on the pharmacy shelf retains its full label-declared potency.

• 30ml and 60ml Pack Coverage: From dark amber bottles to drip-off embossed cartons, metallic labels, and company-logo printed caps — Saar Biotech’s packaging options help antibiotic brands stand out at pharmacy level.

Cefixime Oral Suspension is manufactured and supplied by Saar Biotech for the following established clinical indications, making it a versatile antibiotic for pediatric and adult infectious disease management:

• Acute Otitis Media: Middle ear infections in children caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Cefixime’s once-daily dosing is particularly convenient for pediatric compliance.

• Pharyngitis & Tonsillitis: Streptococcal pharyngitis and tonsillitis in patients who are penicillin-allergic or where macrolide therapy is not preferred.

• Acute Bronchitis: Bacterial bronchitis and acute exacerbations of chronic bronchitis in adults.

• Urinary Tract Infections: Cystitis, pyelonephritis, and other UTIs caused by susceptible Enterobacteriaceae.

• Uncomplicated Gonorrhoea: Single-dose therapy for uncomplicated gonococcal infections.

Schedule H — Requires valid medical prescription. Complete full course of therapy.

Clinical Mechanism of Action

Cefixime is a third-generation cephalosporin that exerts bactericidal activity through inhibition of bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), particularly PBP-3 in Gram-negative organisms, which are enzymes responsible for the final stages of peptidoglycan cross-linking. By inhibiting transpeptidase activity, Cefixime prevents the formation of cross-links between peptidoglycan chains, leading to the accumulation of incomplete cell wall precursors, activation of autolytic enzymes, and ultimately bacterial cell lysis and death.

The third-generation status of Cefixime confers enhanced activity against Gram-negative bacilli (including Enterobacteriaceae and H. influenzae) while maintaining activity against Gram-positive organisms such as Streptococcus pneumoniae. Its enhanced stability against beta-lactamases produced by many Gram-negative organisms further extends its clinical utility.

Manufacturing Integrity

• Cefixime Suspension Uniformity: Cefixime is a poorly soluble API that must be uniformly suspended to ensure consistent dosing. Our suspending agent system and validated mixing process guarantee homogeneous API distribution throughout the 30ml and 60ml bottles.

• pH and Stability Management: Cefixime is susceptible to hydrolytic degradation at non-optimal pH levels. The suspension vehicle is pH-buffered to maintain Cefixime’s chemical stability for 24 months under tropical storage conditions.

• Taste Masking: Mango and mixed fruit flavour systems are engineered to mask Cefixime’s bitterness without compromising the clean, pleasant taste profile that drives pediatric compliance.

• Rapid Absorption: Cefixime is well absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within 2–4 hours of oral administration. The suspension formulation provides predictable absorption even in pediatric patients with varying gastrointestinal transit times.

• Extended Half-Life: With a half-life of approximately 3–4 hours, Cefixime supports once-daily or twice-daily dosing, reducing the dosing burden for patients and caregivers and improving compliance — a key marketing advantage over antibiotics requiring more frequent dosing.

• Tissue Penetration: Cefixime achieves therapeutic concentrations in the respiratory tract, middle ear fluid, and urinary tract, making it effective for its approved indications. This tissue penetration profile is a key clinical message for prescriber detailing.

• Seasonal Repeat Demand: Pediatric antibiotics are among the highest-frequency repurchase pharmaceutical products in the Indian market, particularly during monsoon and winter respiratory illness seasons. A well-positioned Cefixime brand generates consistent prescription cycles.

• 30ml and 60ml Pack Logic: The 30ml format is ideal for short pediatric treatment courses, while the 60ml format covers extended courses and adult dosing — giving B2B partners flexibility across patient populations.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Cefixime Oral Suspension from our dedicated oral suspension manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Oral suspension manufacturing area with controlled processing, automated bottle filling, capping, labelling, and carton packing lines suited for 30ml and 60ml presentations. Our high-shear mixing equipment ensures uniform Cefixime dispersion.

• Capacity: Scalable from brand-entry launches to large commercial batches; 160×60ml and 200×30ml distributor dispatch configurations available.

• Quality Lab: In-house GLP-certified lab with validated HPLC assay for Cefixime, plus pH, viscosity, suspension uniformity, MLT, and fill volume checks on every batch.

• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.

• Packaging: 30ml and 60ml PET or dark amber bottles; sticker label, metallic label, drip-off carton, brand embossed carton, measuring cup, printed cap, with-carton or without-carton supply. Both 100mg and 200mg strengths supported.

• MOQ: Starting at 5,000–10,000 units per SKU; volume-based pricing for repeat orders.

1. Warehouse Conditions: Store below 30°C in a cool, dry environment. Do not freeze — sub-zero temperatures will disrupt the suspension matrix and cause irreversible caking at the base of the bottle.
2. Shake Well Before Every Dose: This is the single most important user instruction for a suspension product. Proper shaking ensures Cefixime is uniformly redispersed.
3. Measuring Cup Use: A calibrated measuring cup must accompany the bottle. Household spoons are unreliable for accurate dosing — particularly important for weight-based pediatric dosing.
4. Light Protection: Dark amber bottles and outer cartons protect the suspension from light-induced degradation.

Every commercial batch of Cefixime Oral Suspension is quarantined until it passes a comprehensive analytical release protocol:

• HPLC Assay: Quantification of Cefixime 100mg or 200mg per 5ml against IP specifications — the primary release test ensuring label claim accuracy.
• Suspension Uniformity & Re-Dispersibility: Sediment behaviour and post-shaking uniformity are evaluated to ensure dose-to-dose consistency.
• pH & Viscosity Testing: The suspension’s pH and flow characteristics are monitored to maintain stability and accurate pourability.
• Microbial Limit Testing (MLT): IP-compliant microbiological testing confirming absence of specified pathogens — particularly important for pediatric oral products.
• Fill Volume & Pack Inspection: Automated fill-volume checks, cap torque, measuring-cup inclusion, label placement, and carton accuracy are verified before dispatch.
• Certificate of Analysis (COA): Issued with every B2B batch.

• Allergic Reactions: Risk of hypersensitivity reactions in patients with penicillin allergy (cross-reactivity). Discontinue if allergic symptoms appear.
• Gastrointestinal Effects: Diarrhoea, nausea, and abdominal pain are the most common adverse effects. Pseudomembranous colitis has been reported with cephalosporins; discontinue if severe diarrhoea occurs.
• Contraindications: Known hypersensitivity to cephalosporins. Severe renal impairment (dose adjustment required).
• Drug Interactions: May reduce the effectiveness of oral contraceptives. Increased nephrotoxicity with aminoglycosides and potent diuretics.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Cefixime Oral Suspension, please use the B2B enquiry form below.